Biocytogen (02315.HK) will participate in the 43rd Annual J.P. Morgan Healthcare Conference (JPM) and other satellite conferences, which will be held in San Francisco, California, USA, from January 13-16, 2025.

Dr. Chaoshe Guo, Vice President and Global BD Head of Biocytogen will attend the following conferences along with the Business Development & Licensing (BDL) team to discuss and explore partnerships for Biocytogen’s fully human antibody platforms and sequence library.

• Jan 12, 8th Annual BFC Global Healthcare BD & Investment Conference
• Jan 13-16, 43rd Annual J.P. Morgan Healthcare Conference
• Jan 13-15, Biotech Showcase 2025
• Jan 13-16, BIO Partnering @ JPM Week

In addition, Dr. Chaoshe Guo will participate in the roadshow at the 8th Annual BFC Global Healthcare BD & Investment Conference, where he will present the company’s innovative R&D achievements and share future development plans. We sincerely invite you to join us, engage in insightful discussions, and explore potential collaboration opportunities.

• Time: January 12, 16:00-16:15 (PT); 19:00-19:15 (ET)
• Location: The St. Regis, San Francisco

Our Discovery Platforms

The RenMice^® series was officially launched by Biocytogen in 2023 as a powerful platform for the discovery of fully human antibodies and TCRs.

As of now, significant milestones have been achieved, including:

• A library of over 400,000 off-the-shelf antibody molecules targeting around 1,000 antigens, with approximately 150 partnerships already established.
• Over 40 PCC molecules, accelerating preclinical development and translational research.

The key antibody projects span major disease areas and diverse therapeutic modalities：

• Inflammatory and autoimmune diseases: ST2, OSM, KIT, CLEC7A etc.
• Metabolic diseases: GIP, GIPR, IL11, IL11RA, GFRAL, LGALS3, ASGR1, SCG3 etc.
• Neurological diseases: CLEC10A, SEMA7A, CGRP, LOX1 etc.
• Bispecific antibody-drug conjugates (BsADC): DLL3× B7H3, DLL3×SEZ6, HER3×MET, PTK7×TROP2, EGFR×5T4, 5T4×MUC1 etc.
• Heavy chain-only antibodies (HCAb): 4-1BB, HER3, PTK7, TFR1, MUC16, VEGFA, GPRC5D, FAP etc.

In 2024, we achieved sustained rapid growth, with our partner network expanding further across the Asia-Pacific, Europe, and the United States. At the same time, we entered into several strategic agreements for different therapeutic modalities:

• ADC Therapies: Radiance; ABL Bio; SOTIO; IDEAYA; Adcendo ApS
• Multi-Target Antibodies: Gilead
• TCR-mimic Antibodies: BioCopy

To explore licensing and collaboration opportunities, please contact BD-Licensing@biocytogen.com to schedule a 1-on-1 meeting.